Peter Attia· MD
20% of cancers have a PI3 kinase mutation.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
20% of cancers have a PI3 kinase mutation.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the fact that 20% of cancers have PI3 kinase, intrinsic mutations in one of the isoforms of PI3 kinase, most commonly alpha
It was also quite clear to me that many cancers have emerged because of activation of PI3 kinase. The fact that mutations in PI3 kinase were picked up in Bert Vogelstein's laboratory in colorectal cancer and ultimately shown to be in many types of cancers led the charge to actually develop an inhibitor because by then it was clear that other mutant tyrosine kinases when they were hypermutated or hyperproduced in cells, could be drugged, and those would be effective ways to block cancer growth.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.